Stock comparison
Exelixis
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EXEL
Exelixis
Market cap
$12.61B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EXEL | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 75B | IDXX |
| Benjamin Graham | 74B | 80A | IDXX |
| Philip Fisher | 74B | 75B | IDXX |
| Peter Lynch | 58C | 71B | IDXX |
| Joel Greenblatt | 60C | 83C | IDXX |
| Charlie Munger | 71B | 87A | IDXX |
| Terry Smith | 80A | 84A | IDXX |
Side-by-side metrics
| Metric | EXEL | IDXX |
|---|---|---|
| Market cap | $12.61B | $44.12B |
| P/E (TTM) | 15.3x | 39.0x |
| EV/EBIT | 14.2x | 31.6x |
| ROIC (TTM) | 35.01% | 40.66% |
| Gross margin | 96.44% | 62.05% |
| Net margin | 35.08% | 24.63% |
| Revenue CAGR 5y | 12.76% | 7.56% |
| EPS CAGR 5y | 40.93% | 10.79% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EXEL leads on
- Debt / Equity0.1xvs 0.7x+87%
- EPS CAGR 5y40.93%vs 10.79%+74%
- P/E (TTM)15.3xvs 39.0x+61%
- EV/EBIT14.2xvs 31.6x+55%
IDXX leads on
- Market cap$44.12Bvs $12.61B+71%
- ROIC (TTM)40.66%vs 35.01%+14%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.